CORONA Remedies Secures EU-GMP Certifications for Hormone and OSD Facilities
CORONA Remedies Limited received EU-GMP certification for its Hormone facility and renewed approval for its Oral Solid Dosage (OSD) facility after an April 2026 inspection. This strengthens global manufacturing and quality credentials, aiming to serve Indian and international markets.
EU-GMP certifications are significant for pharmaceutical companies as they open up access to regulated markets, thereby enhancing the company's global reach and potential revenue.
The company has received EU-GMP certifications for its manufacturing facilities, which is a positive development for its global expansion and quality standards.
CORONA Remedies Limited has announced that it has received European Union Good Manufacturing Practice (EU-GMP) Compliance Certification for its Hormone manufacturing facility and a renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility located in Bhayla, Ahmedabad. These accreditations follow an EUDRA GMP inspection conducted in April 2026.
These certifications are significant milestones that bolster CORONA's global manufacturing and quality standards, underscoring the company's dedication to world-class quality systems, scientific innovation, and manufacturing capabilities aligned with international benchmarks.
Mr. Viral Sitwala, Executive Director of CORONA Remedies Limited, commented, "We view this accreditation as a reflection of our unwavering commitment to quality and our philosophy of 'One World. One Quality.' By adopting uniform global practices, we aim to serve both the Indian market and other regulated/semi-regulated markets from this facility. Backed by strong scientific expertise, rapidly expanding manufacturing capabilities, and a clear strategic vision, we remain committed to advancing accessible, high-quality healthcare in India while taking our Hormone portfolio to global markets — driven by our belief: 'THINK HORMONE… THINK CORONA.'"
Founded in 2004, CORONA Remedies Limited is a fast-growing pharmaceutical company in India, focusing on women’s healthcare, cardio-diabetes, pain management, and urology therapies. The company operates WHO-GMP/EU GMP-certified manufacturing facilities and R&D centers.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.